Abstract-The cardioprotective effects of E-type prostaglandins (EPs) have been attributed to vasodilatation, inhibition of platelet and neutrophil function (EP 2 mediated), and an unknown "cytoprotective effect." We have hypothesized that selective activation of EP 3 receptors may cause cardioprotection. The prostanoid derivative ONO-AE-248 selectively binds to murine EP 3␣ receptors expressed in Chinese hamster ovary (CHO) cells (K i , 15 nmol/L) and prevents the rise in cAMP caused by forskolin in CHO cells (IC 50 Ϸ1 nmol/L) in which the EP 3␣ receptor had been expressed. In anesthetized rats subjected to regional myocardial ischemia for 25 or 45 minutes and 2 hours of reperfusion, infusion of ONO-AE-248 (5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 IV) caused a significant reduction in infarct size, from 60Ϯ3% (nϭ8) to 36Ϯ6% (nϭ7) and from 78Ϯ2% (nϭ11) to 58Ϯ4% (nϭ9), respectively. The reduction in infarct size caused by ONO-AE-248 in rats subjected to 25 minutes of ischemia and reperfusion was abolished by a selective inhibitor of ATP-sensitive potassium (K ATP ) channels, 5-hydroxydecanoate (nϭ6), and the protein kinase C inhibitors staurosporine (nϭ6) and chelerythrine (nϭ6). In anesthetized rabbits subjected to coronary artery occlusion for 45 or 60 minutes and 2 hours of reperfusion, infusion of ONO-AE-248 (5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 IV) caused a significant reduction in infarct size, from 61Ϯ2% (nϭ10) to 36Ϯ4% (nϭ8) and from 63Ϯ4% (nϭ7) to 42Ϯ4% (nϭ7), respectively. The reduction in infarct size caused by ONO-AE-248 in the rabbit was also abolished by 5-hydroxydecanoate. The cardioprotective effect of ONO-AE-248 in rats or rabbits was not associated with any hemodynamic effects. Selective activation of the prostanoid EP 3 receptor reduces myocardial infarct size in rodents by a mechanism(s) that may involve the activation of protein kinase C and the opening of K ATP channels. 
T he effects of E-type prostaglandins (EPs) are mediated by specific G protein-coupled receptors that activate intracellular signal transduction pathways. EP receptors have been classified into 4 subtypes, EP 1 , EP 2 , EP 3 , and EP 4 . 1 In principle, EP 3 receptors may be coupled to G s , G i , and G q proteins. 1 The G-protein coupling of EP 3 receptors depends on posttranscriptional splicing. The known splice variants (eg, EP 3␣ ) of this receptor family differ within their C-terminal amino acid domain, which appears to determine the class of G protein that responds to receptor stimulation. [2] [3] [4] There is evidence that the EP 3␣ and the EP 3␤ receptor are coupled to G i . 5 Interestingly, EP 3 receptors are expressed on cardiac sarcolemmal membranes and appear to inhibit adenylate cyclase activity via G i . 6 EPs including prostaglandin E 1 (PGE 1 ) exert beneficial effects on biochemical, electrocardiographic, and functional indices of myocardial ischemia/reperfusion injury [7] [8] [9] and reduce myocardial infarct size. 10 The cardioprotective effects of these eicosanoids may be secondary to a reduction in afterload, an increase in coronary blood flow, inhibition of platelet function, and/or inhibition of the activation and extravasation of polymorphonuclear cells. 11 All of these effects are secondary to the activation of EP 2 receptors, which activate G s and cause an activation of adenylate cyclase. 1 In addition, the protection of isolated cells or organs by prostaglandins has been attributed to an ill-defined "cytoprotective" or "cardioprotective" effect of these agents. The mechanism(s) or the prostanoid receptor(s) mediating this effect is unknown. 12 In 1995 through 1996, we discovered that the cardioprotective effects of EPs are due, at least in part, to activation of EP 1 or EP 3 receptors, which in turn leads to the opening of ATP-sensitive potassium (K ATP ) channels. 10, 13 This hypothesis is supported by the following findings: (1) The cardioprotective effects of PGE 1 (nonselective agonist for all EP receptors) and sulprostone (selective agonist of EP 1 and EP 3 receptors) are abolished by inhibition of K ATP channels with glibenclamide or 5-hydroxydecanoate (5-HD). 10, 13 (2) Sulprostone causes cardioprotection without having any hemodynamic (EP 2 -mediated) effects. 13 (3) Activation of EP 1 and EP 3 receptors may result in activation of protein kinase C (PKC) and the opening of K ATP channels 1, 14 Because EP 3 receptors are expressed on cardiomyocytes and are upregulated after ischemia of the heart, 6, 15 we hypothesized that it is the activation of EP 3 , rather than of EP 1 , receptors that accounts for the cardioprotective and/or cytoprotective effects of EPs.
The overall aim of this study was to elucidate whether selective activation of prostanoid EP 3 receptors reduces myocardial infarct size in anesthetized rodents. We report the discovery of a prostanoid derivative, ONO-AE-248 ( Figure  1 ), which selectively binds and activates EP 3␣ receptors in Chinese hamster ovary (CHO) cells in which this receptor has been expressed. Subsequently, we have investigated whether ONO-AE-248 reduces the infarct size caused by regional myocardial ischemia and reperfusion in anesthetized rats and rabbits. In addition, we have investigated whether the observed reduction in infarct size caused by ONO-AE-248 is attenuated by the K ATP -channel blocker 5-HD (in rats and rabbits) or by the PKC inhibitors staurosporine and chelerythrine (rats).
Methods

Receptor Binding Studies
Cloned prostanoid receptors (EP 1 , EP 2 , EP 3␣ , EP 4 , FP, TP, and IP) were expressed (separately) in CHO cells. The transfection of the respective cDNAs into CHO cells was performed as previously described. 16 In brief, CHO cells were cultured for 72 hours, and thereafter, membrane fractions were prepared. 16 The standard assay mixture used in the subsequent binding studies contained the following: (1) 
Measurement of Forskolin-Stimulated cAMP Formation in CHO Cells
Activation of EP 3␣ or EP 3␤ receptors with specific agonists results in a reduction of the intracellular levels of cAMP (see introduction). To elucidate whether ONO-AE-248 attenuates the rise in cAMP caused by forskolin in CHO cells expressing murine EP 3␣ receptors, these cells were seeded (10 5 per well) in 24-well plates and cultured for 48 hours. Cells were washed with modified Eagle's medium containing 1% (wt/vol) BSA and 10 mmol/L HEPES-NaOH buffer (pH 7.4) and subsequently preincubated (10 minutes at 37°C) in 450 L of this buffer containing 3-isobutyl-1-methylxanthine (1 mmol/L). Modified Eagle's medium (50 L) containing 10 mol/L forskolin and appropriate concentrations of ONO-AE-248 or PGE 2 were then added and incubated for 10 minutes at 37°C. The reaction was terminated by addition of 500 L of 10% (wt/vol) trichloroacetic acid solution, and the generated cAMP was determined by radioimmunoassay. The amounts of cAMP generated by forskolin in the presence of PGE 2 or ONO-AE-248 were expressed as a percent of the amounts of cAMP generated by forskolin alone (control). The cDNAs of the prostanoid receptors were obtained from Dr S. Narumiya and Dr A. Ichikawa of Kyoto University, Kyoto, Japan.
Rodent Models of Myocardial Infarction
Ninety-five male Wistar rats (240 to 350 g; Tucks, Reyleigh, Essex, UK) were anesthetized (thiopentone sodium, 120 mg/kg IP). After tracheotomy and ventilation (70 strokes/min; tidal volume, 8 to 10 mL/kg; inspiratory oxygen concentration, 30%; positive endexpiratory pressure, 1 to 2 mm Hg resulting in PCO 2 values of 36 to 44 mm Hg and PO 2 values of Ͼ150 mm Hg), the animals were instrumented for the measurement of systemic hemodynamics. A thoracotomy was then performed and a suture placed around the left anterior descending coronary artery (LAD). The LAD was occluded (25 or 45 minutes) and reperfused for 2 hours. After injection of Evans blue dye (1 mL IV) to stain the area at risk (AR), the heart was removed and cut into 4 or 5 horizontal slices. The AR was determined by computer-assisted planimetry (Leica, Quantimed 500). Subsequently, the heart slices were weighed and incubated in p-nitro blue tetrazolium (NBT, 0.5 mg/mL; 20 minutes at 37°C) to stain the areas of viable and infarcted myocardium, which were quantified by planimetry. The AR and infarct size were automatically calculated and expressed as a percent of the left ventricle or of the AR, respectively.
In a separate study, 49 male New Zealand White rabbits (2.5 to 3.0 kg; Foxfield, Petersfield, Hampshire, UK) were premedicated (Hypnorm, 0.1 mL/kg IM containing 0.315 mg/mL fentanyl citrate and 10 mg/mL fluanisone) and anesthetized (pentobarbitone, 20 mg/kg IV). After tracheotomy and ventilation (36 to 40 strokes/min; tidal volume, 18 to 20 mL), a thoracotomy was performed and a suture placed around the first anterolateral branch of the left coronary artery (LAL). Hemodynamic parameters (left ventricular systolic pressure; mean arterial blood pressure, MAP; heart rate, HR; and pressure-rate index, PRI, an indicator of myocardial oxygen consumption) were measured. The LAL was occluded (45 or 60 minutes) and opened to allow reperfusion (2 hours). The AR was determined by staining of the perfused myocardium (Evans blue dye), and infarct size was determined by staining of the AR with NBT as previously described. 10, 17 Experimental Design (In Vivo Studies)
The first study was designed to evaluate whether ONO-AE-248 reduces myocardial infarct size in the anesthetized rat. The following 4 experimental groups were studied: (1) LAD occlusion (45 minutes) and reperfusion (2 hours) plus infusion of vehicle (0.15% Tween-80/0.015% ethanol in saline), starting 10 minutes before LAD occlusion and maintained throughout the experiment (nϭ11); (2) LAD occlusion (45 minutes) and reperfusion (2 hours) plus infusion of ONO-AE-248 (5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 , nϭ9), starting 10 minutes before LAD occlusion and maintained throughout the experiment; (4) sham operation and infusion of ONO-AE-248 (nϭ3).
The second study was designed to investigate whether a larger reduction in infarct size can be obtained with ONO-AE-248 when the ischemic period is reduced from 45 to 25 minutes. Having documented that ONO-AE-248 causes a substantial (Ϸ40%) reduction in myocardial infarct size under these experimental conditions, we subsequently investigated the role of the activation of K ATP channels and/or PKC in this cardioprotective effect. To do this, the following additional 13 experimental groups were studied: (1) LAD occlusion (25 minutes) and reperfusion (2 hours) plus infusion of vehicle as above (nϭ8); (2) LAD occlusion and reperfusion plus infusion of ONO-AE-248 (5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 , nϭ7); (3) sham operation (no LAD occlusion) and infusion of vehicle (nϭ3); (4) sham operation and infusion of ONO-AE-248 (nϭ3); (5) LAD occlusion and reperfusion plus injection of 5-HD (5 mg/kg IV 10 minutes before LAD occlusion, nϭ6); (6) sham operation and injection of 5-HD (nϭ3); (7) LAD occlusion and reperfusion plus administration of 5-HD (as above) and ONO-AE-248 (as above, nϭ6); (8) LAD occlusion and reperfusion plus injection of staurosporine (1 g/kg IV 10 minutes before LAD occlusion, nϭ6); (9) sham operation and injection of staurosporine (nϭ3); (10) LAD occlusion and reperfusion plus administration of staurosporine (as above) and ONO-AE-248 (as above, nϭ6); (11) LAD occlusion and reperfusion plus injection of chelerythrine (0.7 mg/kg IV 10 minutes before LAD occlusion, nϭ6); (12) sham operation and injection of chelerythrine (nϭ3); and (13) LAD occlusion and reperfusion plus administration of chelerythrine (as above) and ONO-AE-248 (as above, nϭ6).
In a third study, we investigated whether ONO-AE-248 reduces myocardial infarct size in the anesthetized rabbit. To do this, the following 3 experimental groups were studied: (1) LAL occlusion (45 minutes) and reperfusion (2 hours) plus infusion of vehicle (as above, nϭ10); (2) LAL occlusion and reperfusion plus infusion of ONO-AE-248 (5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 , nϭ8); and (3) sham operation (no LAL occlusion) and infusion of ONO-AE-248 (nϭ3).
The fourth study was designed to elucidate whether the reduction in infarct size afforded by ONO-AE-248 in the rabbit is attenuated by pretreatment of the animals with the K ATP -channel blocker 5-HD. The following 4 experimental groups were studied: (1) LAL occlusion (60 minutes) and reperfusion (2 hours) plus infusion of vehicle (as above, nϭ7); (2) LAL occlusion and reperfusion plus infusion of ONO-AE-248 (as above, nϭ7); (3) LAL occlusion and reperfusion plus injection of 5-HD (5 mg/kg IV, nϭ7); and (4) LAL occlusion and reperfusion plus injection of 5-HD and ONO-AE-248 (nϭ7).
Measurement of the Plasma Levels of Troponin T (TnT) in the Rat
At the end of the experiment (study 2, groups 1 [nϭ8], 2 [nϭ7], and 3 [nϭ3]), a 1-mL blood sample was obtained from the carotid cannula and centrifuged to obtain plasma. The concentration of TnT was determined by the short turn-around-time assay (STAT provided by Boehringer Mannheim) using an Elecixs system 2010.
Drugs
Chelerythrine and staurosporine were dissolved in dimethyl sulfoxide (final concentration in vivo Ͻ0.2% for dimethyl sulfoxide), ONO-AE-248 (prostanoic acid derivative, molecular weight of 380.5) was dissolved in ethanol, Tween-80, and saline (final concentration in vivo, Ͻ0.1% for ethanol and 0.1% for Tween-80).
5-HD was dissolved in saline. Unless otherwise stated, all compounds were obtained from Sigma Chemical Co. Thiopentone sodium (Intraval) was obtained from May & Baker Ltd. Chelerythrine and staurosporine were from Calbiochem.
Statistical Analysis
All values in the text, figures, and tables are expressed as the meanϮSEM of n observations. Statistical analysis was performed by 1-way ANOVA followed, if appropriate, by Bonferroni's test for multiple comparisons. A value of PϽ0.05 was considered statistically significant.
Results
Specific Binding of ONO-AE-248 to Membranes of CHO Cells Expressing EP, FP, TP, or IP Receptors
In CHO cells expressing the murine EP 3␣ 
ONO-AE-248 Attenuates the Forskolin-Induced Rise in Intracellular cAMP in CHO Cells Transfected With the Murine EP 3␣ Receptor
To elucidate whether binding of ONO-AE-248 to the EP 3␣ receptor activates signal transduction events (ie, reduction in intracellular cAMP), whole CHO cells in which the EP 3␣ receptor had been expressed were challenged with forskolin, which increases the intracellular levels of cAMP, in the absence (control) or presence of PGE 2 , a nonselective agonist of all EP receptors; sulprostone, an EP 1 -and EP 3 -receptor agonist; or ONO-AE-248. PGE 2 (IC 50 Ϸ0.1 nmol/L), sulprostone (IC 50 Ϸ0.1 nmol/L), or ONO-AE-248 (IC 50 Ϸ1 nmol/L) caused a concentration-dependent inhibition of the rise in intracellular cAMP caused by forskolin. At a concentration of 10 nmol/L, the rise in cAMP caused by forskolin was abolished by sulprostone, reduced to 12Ϯ2% of control by PGE 2 , and reduced to 42Ϯ2% of control by ONO-AE-248 (nϭ3). Thus, activation of EP 3␣ receptors with ONO-AE-248, sulprostone, or PGE 2 attenuates the rise in cAMP caused by forskolin. Thus, ONO-AE-248 is an agonist at the EP 3␣ receptor.
ONO-AE-248 Reduces Myocardial Infarct Size in Rats
Study 1 in Rats: 45 Minutes of LAD Occlusion
Values for MAP, HR, and PRI measured during the course of the experiment (study 1) are given in Table 2 . Baseline hemodynamic data were similar (PϾ0.05) in all groups studied. In rats subjected to sham operation or LAD occlusion and reperfusion, ONO-AE-248 did not cause any significant hemodynamic effects. The AR was similar in rats subjected to LAD occlusion and then treated with either vehicle (control, 54Ϯ4%, nϭ11) or ONO-AE-248 (57Ϯ2%, nϭ9, PϾ0.05).
When compared with vehicle-treated control animals, infusion of ONO-AE-248 caused a significant reduction in infarct size, from 78Ϯ2% (control, nϭ11) to 58Ϯ4% (PϽ0.05, nϭ9) of the AR.
Study 2 in Rats: 25 Minutes of LAD Occlusion
MAP, HR, and PRI were measured during the course of the experiment (study 2, data not shown). Baseline hemodynamic data were similar (PϾ0.05) in all groups studied. In rats subjected to LAD occlusion for 25 minutes plus 2 hours of reperfusion, ONO-AE-248 did not cause any significant hemodynamic effects. Moreover, none of the other interventions studied (5-HD, staurosporine, or chelerythrine) caused any significant hemodynamic effects when given to either sham-operated rats or rats subjected to LAD occlusion and reperfusion, in either the absence or presence of ONO-AE-248. In the 13 experimental groups studied, the AR ranged from 45Ϯ2% to 56Ϯ2% and was not different between groups (PϾ0.05). When compared with vehicle-treated control animals, infusion of ONO-AE-248 caused a significant reduction in infarct size, from 60Ϯ3% (control, nϭ8) to 36Ϯ6% (PϽ0.05, nϭ7) of the AR (Figure 2a) . The reduction in infarct size afforded by ONO-AE-248 was abolished by pretreatment of rats with 5-HD (Figure 2a) . Interestingly, 5-HD alone did not affect the infarct size in rats subjected to regional myocardial ischemia/reperfusion (Figure 2a) . Similarly, the reduction in infarct size afforded by ONO-AE-248 was abolished by pretreatment of rats with the PKC inhibitors 259Ϯ20  259Ϯ19  258Ϯ19  253Ϯ18  251Ϯ20  251Ϯ20  247Ϯ20  238Ϯ22 PRI, mm Hg/min ϫ 10
staurosporine ( Figure 2b ) and chelerythrine ( Figure 2c ). Neither staurosporine nor chelerythrine, however, affected the infarct size caused by regional myocardial ischemia and reperfusion in the rat (Figure 2b and 2c) .
To exclude the possibility that ONO-AE-248 interferes with the NBT staining procedure, 3 rats were subjected to regional myocardial ischemia (25 minutes) and reperfusion (2 hours). The heart was removed, and the AR was incubated with NBT (as above) in the presence of 10 mol/L ONO-AE-248. The infarct size in these experiments was 62Ϯ5% (nϭ3) and hence, not different from control. Thus, ONO-AE-248 does not interfere with the staining procedure.
ONO-AE-248 Reduces Myocardial Ischemia-Mediated TnT Increases in the Rat
In rats subjected to sham operation (surgical procedure only), the plasma levels of TnT were below the detection limit of the assay (Ͻ0.01 g/L, nϭ3). In contrast, LAD occlusion (25 minutes) and reperfusion (2 hours) resulted in a significant increase in the plasma levels of TnT, to 65Ϯ14 g/L (nϭ8). Treatment of rats subjected to regional myocardial ischemia and reperfusion with ONO-AE-248 attenuated this rise in the plasma levels of TnT to 21Ϯ6 g/L (PϽ0.05, nϭ7).
ONO-AE-248 Reduces Myocardial Infarct Size in Rabbits
Study 3 in Rabbits: 45 Minutes of LAL Occlusion
Values for MAP, HR, and PRI measured during the course of the experiment (study 3) are given in Table 2 . Baseline hemodynamic data were similar (PϾ0.05) in all groups studied. In rabbits subjected to LAL occlusion for 45 minutes plus 2 hours of reperfusion, ONO-AE-248 did not cause any significant hemodynamic effects. The AR was similar in rabbits subjected to LAL occlusion for 45 minutes and treated with either vehicle (control, 40Ϯ2%, nϭ10) or ONO-AE-248 (48Ϯ3%, nϭ8). When compared with vehicle-treated control animals, infusion of ONO-AE-248 caused a significant reduction in infarct size, from 61Ϯ2% (control, nϭ10) to 36Ϯ4% (PϽ0.05, nϭ8) of the AR.
Study 4 in Rabbits: 60 Minutes of LAL Occlusion
MAP, HR, and PRI were measured during the course of the experiment (study 4, data not shown). Baseline hemodynamic data were similar (PϾ0.05) in all groups studied. In rabbits subjected to LAL occlusion for 60 minutes plus 2 hours of reperfusion, ONO-AE-248 did not cause any significant hemodynamic effects. In the 4 experimental groups studied, the AR ranged from 38Ϯ4% to 47Ϯ2% and was not different between groups (PϾ0.05). When compared with control animals, infusion of ONO-AE-248 caused a significant reduction in infarct size, from 63Ϯ4% (control, nϭ7) to 42Ϯ4% (PϽ0.05, nϭ7) of the AR (Figure 3) . Pretreatment with 5-HD abolished the reduction in infarct size afforded by Figure 2 . a, ONO-AE-248 reduces the infarct size in rats caused by regional myocardial ischemia (25 minutes) followed by reperfusion (2 hours). When compared with vehicle-treated controls (Con, nϭ8), infusion of the EP 3 -receptor agonist ONO-AE-248 (5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 IV) caused a significant reduction in myocardial infarct size (ONO, nϭ7). The cardioprotective effect of ONO-AE-248 is prevented by pretreatment of rats with 5-HD (5 mg/kg IV; 5-HDϩONO, nϭ6), whereas 5-HD alone does not affect infarct size in rats treated with vehicle for ONO-AE-248 (5-HD, nϭ6) . b, The cardioprotective effect of ONO-AE-248 is prevented by pretreatment of rats with staurosporine (1 g/kg IV; StauϩONO, nϭ6), whereas staurosporine alone (Stau, nϭ6) does not affect infarct size in rats treated with vehicle for ONO-AE-248. c, The cardioprotective effect of ONO-AE-248 is prevented by pretreatment of rats with chelerythrine (0.7 mg/kg IV, ChelϩONO, nϭ6), whereas chelerythrine alone (Chel, nϭ6) does not affect infarct size in rats. *PϽ0.05 when compared with vehicle control. Figure 3 . Blockade of K ATP channels abolishes the reduction in infarct size caused by ONO-AE-248 in rabbits subjected to 60 minutes of coronary artery occlusion followed by 2 hours of reperfusion. When compared with vehicle-treated controls (Con, nϭ7), infusion of ONO-AE-248 (ONO, nϭ7) caused a significant reduction in infarct size. The cardioprotective effect of ONO-AE-248 is prevented by pretreatment of rabbits with 5-HD (5 mg/kg IV, 5-HDϩONO, nϭ7), whereas 5-HD alone does not affect infarct size in rabbits treated with vehicle for ONO-AE-248 (5-HD, nϭ7). *PϽ0.05 when compared with vehicle control.
ONO-AE-248 (Figure 3) . However, 5-HD alone did not affect the infarct size when compared with vehicle control (Figure 3) .
Discussion
This study demonstrates that the prostanoid derivative ONO-AE-248 selectively binds to EP 3␣ receptors expressed in CHO cells. In these cells, ONO-AE-248 also attenuates the rise in cAMP caused by forskolin, suggesting that ONO-AE-248 activates G i in these cells. Thus, ONO-AE-248 is a selective agonist of the EP 3␣ receptor. We also report that ONO-AE-248 reduces the myocardial infarct size in rats and rabbits subjected to coronary artery occlusion and reperfusion. The reduction in infarct size caused by ONO-AE-248 was determined by staining of the viable myocardium within the AR with the formazan dye NBT. The reduction in infarct size caused by ONO-AE-248 as determined by this staining procedure is indeed due to a reduction in myocardial tissue injury, as ONO-AE-248 also attenuated the increase in the plasma levels of TnT caused by regional myocardial ischemia in the rat. There is good evidence that a rise in the plasma levels of cardiac TnT are specific for myocardial tissue injury. 18 Unlike plasma levels of creatine phosphokinase or lactic dehydrogenase, which are elevated in open-chest models of myocardial infarction due to the surgical procedure (K.Z. and C.T., unpublished observations, 1998), the thoracotomy employed here did not result in any detectable rise in the plasma levels of TnT. Because ONO-AE-248 also did not interfere with the NBT staining procedure used, our data strongly support the conclusion that ONO-AE-248 does indeed cause a significant reduction in myocardial infarct size.
What, then, is the mechanism(s) by which ONO-AE-248 causes a significant reduction in the degree of necrosis caused by myocardial ischemia and reperfusion? Clearly, a reduction in blood pressure and hence, myocardial oxygen consumption does not account for the cardioprotective effects of ONO-AE-248 reported here, because this EP 3 -receptor agonist did not cause any hemodynamic effects in either rats or rabbits. This also supports the notion that at the doses used in vivo, ONO-AE-248 is a selective EP 3 -receptor agonist and does not activate EP 2 receptors, which mediate the hypotension caused by EPs. This finding is important, because it demonstrates that the cardioprotective effects of ONO-AE-248 are, unlike those of prostacyclin, iloprost, or (at higher doses) PGE 1 , not limited by hemodynamic side effects.
We suggest that the observed reduction in infarct size by ONO-AE-248 is due to the activation of EP 3 receptors in vivo. It is unlikely that the dose of ONO-AE-248 used in this study is sufficient to activate other EP receptors for the following reasons. We demonstrated that the K i value of ONO-AE-248 at the EP 3 receptor is 0.015 mol/L, whereas those for the EP 2 and the EP 4 receptors are in the range of 3 to 4 mol/L, and those for the EP 1 , FP, TP, and IP receptors are in excess of 10 mol/L. Because ONO-AE-248 did not cause a significant fall in blood pressure, it is extremely unlikely that the dose of ONO-AE-248 chosen here was sufficient to activate EP 2 receptors. Thus, we propose that it is most likely that the observed effects of ONO-AE-248 are due to the activation of EP 3 receptors. Hohlfeld and colleagues 19 have reported in abstract form that the EP 3 -receptor agonist M&B28767 also causes a substantial (50%) reduction in infarct size in pigs subjected to regional myocardial ischemia. Taken together, these findings support the view that activation of EP 3 receptors does indeed cause a reduction in infarct size.
What, then, is the mechanism(s) by which activation of EP 3 receptors reduces infarct size? The reduction in infarct size caused by either PGE 1 or the EP 1 /EP 3 -receptor agonist sulprostone is at least in part due to the activation and opening of K ATP channels. 10, 13 Here we report that the cardioprotective effect of the selective EP 3 -receptor agonist ONO-AE-248 is, in rats and rabbits, abolished by pretreatment of the animals with 5-HD, a selective blocker of K ATP channels. These findings suggest that activation of EP 3 receptors leads to opening of K ATP channels, which in turn results in cardioprotection. The signal transduction events involved in the cardioprotective effects of ONO-AE-248 are reminiscent of the ones that mediate the potent anti-ischemic effects of "ischemic preconditioning." 20 Preconditioning of the heart and other organs or tissues with ischemia results in the release of adenosine and other mediators (eg, bradykinin, endothelin-1, angiotensin II, and catecholamines), which activate G protein-coupled receptors resulting in (1) translocation of PKC from the cytosol to the cell membrane, (2) activation of PKC, (3) opening of K ATP channels, and (4) ultimately, cardioprotection. 20, 21 The reduction in infarct size afforded by ischemic preconditioning in the rabbit model of myocardial ischemia and reperfusion used here is also abolished by 5-HD. 13 Thus, we have hypothesised that activation of EP 3 receptors by ONO-AE-248, like ischemic preconditioning, may lead to activation of PKC, opening of K ATP channels, and ultimately, cardioprotection. To support this hypothesis, we have demonstrated that the reduction in infarct size caused by ONO-AE-248 in the rat is abolished by 2 chemically distinct inhibitors of PKC, namely, staurosporine, a nonselective PKC inhibitor, and chelerythrine, a selective PKC inhibitor. The doses of staurosporine and chelerythrine employed here have been reported to specifically inhibit the activation of PKC in vivo and ex vivo [22] [23] [24] and also abolish the cardioprotective effects of ischemic preconditioning in rodents. 22, 25 The cytoprotective properties of prostaglandins were first described as the ability of these agents to protect the gastric mucosa against noxious stimuli (eg, ethanol, acid, and hot water). 26 Although the mechanism of these cytoprotective effects of prostaglandins has been elusive, these cytoprotective effects have been suggested to contribute to or account for the protection of certain organs or tissues, including the heart, by prostaglandins against a variety of different noxious stimuli. 12, 26 Thus, cytoprotection is the protection of a tissue by prostaglandins in the absence of alterations in blood flow, inhibition of platelet function, or inhibition of polymorphonuclear cell activation mediated by EP 2 receptors. Activation of EP 3 receptors leads to protection of the myocardium against ischemia, without causing alterations in systemic hemodynamics (vide infra) and presumably, inhibition of the function of blood-borne cells. Thus, activation of these receptors may contribute to or even account for the protection of cardiomyocytes caused by EPs.
In conclusion, this study demonstrates for the first time that (1) ONO-AE-248 selectively binds to EP 3␣ receptors, (2) ONO-AE-248 causes a reduction in intracellular cAMP in CHO cells, in which the EP 3␣ receptor had been expressed, and challenged with forskolin, (3) ONO-AE-248 reduces infarct size in rats and rabbits subjected to regional myocardial ischemia and reperfusion, (4) the cardioprotective effects of ONO-AE-248 are abolished by the K ATP -channel blocker 5-HD (rats and rabbits), and (5) the cardioprotective effects of ONO-AE-248 are abolished by the PKC inhibitors staurosporine and chelerythrine (rats). We speculate that the cytoprotective or cardioprotective effects of EPs are at least in part due to activation by these agents of EP 3 receptors. Our discovery of a selective agonist of the EP 3 receptor provides an important pharmacological tool to elucidate the role of the prostanoid EP 3 receptors in physiology and pathophysiology.
